GFR-话题@MedSci

#GFR#

483篇内容 | 2461人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1534640, encodeId=31a71534640b7, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Thorac Cancer：真实世界中晚期NSCLC患者伴有KRAS、MET、FGFR、RET、BRAF和HER2改变时一线使用免疫检查点抑制剂(ICIs)的疗效, objectType=article, longId=727690, objectId=5f10e2769003, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f10e2769003, replyNumber=0, likeNumber=80, createdTime=2022-05-25, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f10e2769003, moduleTitle=Thorac Cancer：真实世界中晚期NSCLC患者伴有KRAS、MET、FGFR、RET、BRAF和HER2改变时一线使用免疫检查点抑制剂(ICIs)的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f10e2769003)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534639, encodeId=0274153463924, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Thorac Cancer：多中心回顾性研究评估dacomitinib（达可替尼）再挑战EGFR突变NSCLC患者的疗效, objectType=article, longId=727665, objectId=42bae2766592, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=42bae2766592, replyNumber=0, likeNumber=0, createdTime=2022-05-25, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=42bae2766592, moduleTitle=Thorac Cancer：多中心回顾性研究评估dacomitinib（达可替尼）再挑战EGFR突变NSCLC患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=42bae2766592)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534638, encodeId=2c9f153463884, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Thorac Cancer：EGFR阳性老年NSCLC患者吉非替尼进展后单药联合继续吉非替尼可改善患者PFS, objectType=article, longId=727473, objectId=6721e274735c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6721e274735c, replyNumber=0, likeNumber=79, createdTime=2022-05-22, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6721e274735c, moduleTitle=Thorac Cancer：EGFR阳性老年NSCLC患者吉非替尼进展后单药联合继续吉非替尼可改善患者PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6721e274735c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534637, encodeId=b09d153463ea8, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=EGFR四代药初露锋芒！六大奥希替尼耐药处理方案全梳理, objectType=article, longId=727375, objectId=f07fe273752c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f07fe273752c, replyNumber=0, likeNumber=85, createdTime=2022-05-21, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f07fe273752c, moduleTitle=EGFR四代药初露锋芒！六大奥希替尼耐药处理方案全梳理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f07fe273752c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534636, encodeId=b26d153463674, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=JCO：阿美替尼对比吉非替尼对EGFR突变NSCLC一线治疗结果公布（AENEAS研究）, objectType=article, longId=727335, objectId=1e0ee27335dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e0ee27335dd, replyNumber=0, likeNumber=91, createdTime=2022-05-21, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e0ee27335dd, moduleTitle=JCO：阿美替尼对比吉非替尼对EGFR突变NSCLC一线治疗结果公布（AENEAS研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e0ee27335dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534635, encodeId=6bbb153463557, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Lung Cancer：奥希替尼和阿法替尼交替治疗初治EGFR突变的晚期非小细胞肺癌（NSCLC）的疗效和安全性:WJOG10818L, objectType=article, longId=726654, objectId=865fe2665466, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=865fe2665466, replyNumber=0, likeNumber=102, createdTime=2022-05-13, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=865fe2665466, moduleTitle=Lung Cancer：奥希替尼和阿法替尼交替治疗初治EGFR突变的晚期非小细胞肺癌（NSCLC）的疗效和安全性:WJOG10818L, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=865fe2665466)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534634, encodeId=794f1534634cb, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Nat Cancer：JBJ-09-063：非小细胞肺癌治疗的潜在EGFR变构抑制剂, objectType=article, longId=725549, objectId=d86fe255493e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d86fe255493e, replyNumber=0, likeNumber=87, createdTime=2022-04-28, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d86fe255493e, moduleTitle=Nat Cancer：JBJ-09-063：非小细胞肺癌治疗的潜在EGFR变构抑制剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d86fe255493e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534633, encodeId=a94b153463381, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=J Clin Oncol：EGFR抑制剂治疗EGFR扩增的胃食管交界癌的疗效, objectType=article, longId=724167, objectId=fa55e2416717, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa55e2416717, replyNumber=0, likeNumber=96, createdTime=2022-04-14, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa55e2416717, moduleTitle=J Clin Oncol：EGFR抑制剂治疗EGFR扩增的胃食管交界癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa55e2416717)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534630, encodeId=d21c153463085, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=AACR 2022：第四代EGFR抑制剂BLU-945治疗晚期耐药的NSCLC早期结果公布, objectType=article, longId=724026, objectId=c4f1e2402624, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4f1e2402624, replyNumber=0, likeNumber=92, createdTime=2022-04-13, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4f1e2402624, moduleTitle=AACR 2022：第四代EGFR抑制剂BLU-945治疗晚期耐药的NSCLC早期结果公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c4f1e2402624)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534631, encodeId=4a421534631f9, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=AACR重磅之INSIGHT研究：特泊替尼+吉非替尼联合治疗显著改善了伴有MET扩增的EGFR突变阳性NSCLC患者无进展生存期和总生存期, objectType=article, longId=723968, objectId=3207e2396893, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3207e2396893, replyNumber=0, likeNumber=48, createdTime=2022-04-12, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3207e2396893, moduleTitle=AACR重磅之INSIGHT研究：特泊替尼+吉非替尼联合治疗显著改善了伴有MET扩增的EGFR突变阳性NSCLC患者无进展生存期和总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3207e2396893)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534629, encodeId=b6e0153462975, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Clin Cancer Res：FGFR抑制剂Infigratinib单药治疗携带EGFR变异的复发性胶质瘤的疗效, objectType=article, longId=723401, objectId=df51e23401fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df51e23401fa, replyNumber=0, likeNumber=49, createdTime=2022-04-05, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df51e23401fa, moduleTitle=Clin Cancer Res：FGFR抑制剂Infigratinib单药治疗携带EGFR变异的复发性胶质瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df51e23401fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534628, encodeId=f8f11534628f5, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=2022年ESMO专家共识：EGFR突变非小细胞肺癌的治疗, objectType=article, longId=302214, objectId=fba0302214dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fba0302214dc, replyNumber=0, likeNumber=78, createdTime=2022-04-03, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fba0302214dc, moduleTitle=2022年ESMO专家共识：EGFR突变非小细胞肺癌的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fba0302214dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534627, encodeId=e935153462e2c, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=2022 年ESMO专家共识：EGFR突变非小细胞肺癌的治疗, objectType=article, longId=302210, objectId=5b43302210bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b43302210bd, replyNumber=0, likeNumber=80, createdTime=2022-04-03, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b43302210bd, moduleTitle=2022 年ESMO专家共识：EGFR突变非小细胞肺癌的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b43302210bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534626, encodeId=f46f15346262e, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=BMC Cancer：探索晚期EGFR/ALK突变非小细胞肺癌（NSCLC）生存超5年患者的临床特征, objectType=article, longId=302036, objectId=977230203625, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=977230203625, replyNumber=0, likeNumber=108, createdTime=2022-04-01, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=977230203625, moduleTitle=BMC Cancer：探索晚期EGFR/ALK突变非小细胞肺癌（NSCLC）生存超5年患者的临床特征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=977230203625)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534632, encodeId=2107153463266, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=中国亚组数据正式揭晓：泰瑞沙®用于早期EGFR突变肺癌患者辅助治疗，进一步证实中国人群临床获益, objectType=article, longId=301654, objectId=d9c830165485, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9c830165485, replyNumber=0, likeNumber=0, createdTime=2022-03-27, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9c830165485, moduleTitle=中国亚组数据正式揭晓：泰瑞沙®用于早期EGFR突变肺癌患者辅助治疗，进一步证实中国人群临床获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9c830165485)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534625, encodeId=c9a51534625b3, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=J Thorac Oncol: TP53共突变促进EGFR突变肺腺癌的耐药进化, objectType=article, longId=301646, objectId=b80230164678, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b80230164678, replyNumber=0, likeNumber=76, createdTime=2022-03-27, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b80230164678, moduleTitle=J Thorac Oncol: TP53共突变促进EGFR突变肺腺癌的耐药进化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b80230164678)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534624, encodeId=bf6815346246c, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=肺癌EGFR靶向药超全梳理，用法和不良反应一文掌握, objectType=article, longId=301278, objectId=74e23012e858, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74e23012e858, replyNumber=0, likeNumber=72, createdTime=2022-03-22, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74e23012e858, moduleTitle=肺癌EGFR靶向药超全梳理，用法和不良反应一文掌握, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74e23012e858)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534623, encodeId=700515346235c, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Eur J Cancer：EGFR突变型肺癌的组织学转化概率及临床病程, objectType=article, longId=301130, objectId=be42301130c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be42301130c7, replyNumber=0, likeNumber=97, createdTime=2022-03-20, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be42301130c7, moduleTitle=Eur J Cancer：EGFR突变型肺癌的组织学转化概率及临床病程, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=be42301130c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534622, encodeId=6972153462254, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Oncologist：全球多中心真实世界探索EGFR-TKIs治疗罕见EGFR突变NSCLC患者的疗效, objectType=article, longId=300760, objectId=f451300e604a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f451300e604a, replyNumber=0, likeNumber=0, createdTime=2022-03-16, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f451300e604a, moduleTitle=Oncologist：全球多中心真实世界探索EGFR-TKIs治疗罕见EGFR突变NSCLC患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f451300e604a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534621, encodeId=e798153462192, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=J Clin Oncol：ICI联合VEGFR抑制剂治疗晚期肾细胞癌时的主要不良心血管事件风险, objectType=article, longId=300189, objectId=ad87300189e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad87300189e8, replyNumber=0, likeNumber=81, createdTime=2022-03-08, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad87300189e8, moduleTitle=J Clin Oncol：ICI联合VEGFR抑制剂治疗晚期肾细胞癌时的主要不良心血管事件风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad87300189e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

GFR

2020-05-29

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Thorac Cancer：真实世界中晚期NSCLC患者伴有KRAS、MET、FGFR、RET、BRAF和HER2改变时一线使用免疫检查点抑制剂(ICIs)的疗效

2022-05-25

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Thorac Cancer：多中心回顾性研究评估dacomitinib（达可替尼）再挑战EGFR突变NSCLC患者的疗效

2022-05-25

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Thorac Cancer：EGFR阳性老年NSCLC患者吉非替尼进展后单药联合继续吉非替尼可改善患者PFS

2022-05-22

liuyiping (审核中...)

前往app查看评论内容

#GFR#

EGFR四代药初露锋芒！六大奥希替尼耐药处理方案全梳理

2022-05-21

liuyiping (审核中...)

前往app查看评论内容

#GFR#

JCO：阿美替尼对比吉非替尼对EGFR突变NSCLC一线治疗结果公布（AENEAS研究）

2022-05-21

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Lung Cancer：奥希替尼和阿法替尼交替治疗初治EGFR突变的晚期非小细胞肺癌（NSCLC）的疗效和安全性:WJOG10818L

2022-05-13

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Nat Cancer：JBJ-09-063：非小细胞肺癌治疗的潜在EGFR变构抑制剂

2022-04-28

liuyiping (审核中...)

前往app查看评论内容

#GFR#

J Clin Oncol：EGFR抑制剂治疗EGFR扩增的胃食管交界癌的疗效

2022-04-14

liuyiping (审核中...)

前往app查看评论内容

#GFR#

AACR 2022：第四代EGFR抑制剂BLU-945治疗晚期耐药的NSCLC早期结果公布

2022-04-13

liuyiping (审核中...)

前往app查看评论内容

#GFR#

AACR重磅之INSIGHT研究：特泊替尼+吉非替尼联合治疗显著改善了伴有MET扩增的EGFR突变阳性NSCLC患者无进展生存期和总生存期

2022-04-12

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Clin Cancer Res：FGFR抑制剂Infigratinib单药治疗携带EGFR变异的复发性胶质瘤的疗效

2022-04-05

liuyiping (审核中...)

前往app查看评论内容

#GFR#

2022年ESMO专家共识：EGFR突变非小细胞肺癌的治疗

2022-04-03

liuyiping (审核中...)

前往app查看评论内容

#GFR#

2022 年ESMO专家共识：EGFR突变非小细胞肺癌的治疗

2022-04-03

liuyiping (审核中...)

前往app查看评论内容

#GFR#

BMC Cancer：探索晚期EGFR/ALK突变非小细胞肺癌（NSCLC）生存超5年患者的临床特征

2022-04-01

liuyiping (审核中...)

前往app查看评论内容

#GFR#

中国亚组数据正式揭晓：泰瑞沙®用于早期EGFR突变肺癌患者辅助治疗，进一步证实中国人群临床获益

2022-03-27

liuyiping (审核中...)

前往app查看评论内容

#GFR#

J Thorac Oncol: TP53共突变促进EGFR突变肺腺癌的耐药进化

2022-03-27

liuyiping (审核中...)

前往app查看评论内容

#GFR#

肺癌EGFR靶向药超全梳理，用法和不良反应一文掌握

2022-03-22

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Eur J Cancer：EGFR突变型肺癌的组织学转化概率及临床病程

2022-03-20

爆笑小医 (审核中...)

前往app查看评论内容

#GFR#

Oncologist：全球多中心真实世界探索EGFR-TKIs治疗罕见EGFR突变NSCLC患者的疗效

2022-03-16

liuyiping (审核中...)

前往app查看评论内容

#GFR#

J Clin Oncol：ICI联合VEGFR抑制剂治疗晚期肾细胞癌时的主要不良心血管事件风险

2022-03-08

科室
- - 订阅+
  - 更多科室
工具
服务